Introduction Cancer remains a leading cause of death worldwide. While a curative intent is
the aim of any surgical treatment many patients either present with or go onto develop …

Purpose Systemic peripheral T-cell lymphomas (PTCLs) respond poorly to conventional
therapy. To evaluate the efficacy of a dose-dense approach consolidated by up-front high …

Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although
treatment has been standardised in younger patients, no prospective study has been done …

The clinical and molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL), even
beyond the recent WHO reclassification, 1 is well recognized.(For simplicity, this review will …

Abstract Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line
rituximab was gradually introduced between 2003 and 2007, with regional differences. The …

To determine the effect of gender on outcome, the male hazard ratio for progression-free
survival (HRPFS-male) was determined in patients with diffuse large B-cell lymphoma …

This study compared the value of several simple laboratory parameters with known
prognostic models for predicting survival in patients with diffuse large B‐cell lymphoma …

Non-Hodgkin lymphoma (NHL) is one of the most common hematologic malignancies
worldwide. The incidence of NHL has been rising for several decades; however, in the last …

The geriatric nutritional risk index (GNRI) is a simple and well-established nutritional
assessment tool that is a significant prognostic factor for various cancers. However, the role …

Serum albumin (SA) has been shown to be a prognostic marker in many hematological
malignancies and in diffuse large B-cell lymphoma (DLBCL) prior to chemo-immunotherapy …